HOME >> BIOLOGY >> NEWS
Aggressive therapy best for certain AML patients

COLUMBUS , Ohio A new study suggests that acute leukemia patients whose cancer cells show a genetic change that usually predicts a swift return of the disease following remission may remain disease-free longer when given aggressive therapy.

The findings apply to people with acute myeloid leukemia (AML) whose cancer cells have normal-looking chromosomes and a gene mutation called MLL-PTD.

Typically, these AML patients responded poorly following treatment with older standard therapies, often relapsing within a year. Of AML patients with normal chromosomes who lack the mutation, on the other hand, four in 10 are cured.

The new study suggests that treating patients who have the mutation with an aggressive therapy such as an autologous stem cell transplant while they are in remission might significantly extend their disease-free survival.

An autologous transplant uses stem cells taken from the patient's own blood.

The research was led by investigators at the Ohio State University Comprehensive Cancer Center. It is part of a larger study sponsored by the Cancer and Leukemia Group B (CALGB), a clinical cooperative group composed of oncologists from academic medical centers and community hospitals across the nation.

The findings were published in a recent issue of the journal Blood.

Our data is the first to show that AML patients with normal-looking chromosomes and this mutation do as well when treated aggressively as patients who don't have the mutation, says principal investigator Clara D. Bloomfield, professor of internal medicine and an internationally known AML specialist.

About 13,400 new cases of AML are expected this year, and about half will have cancer cells with chromosomes that show distinctive damage. The nature of that damage helps doctors determine a patient's therapy and estimate the patient's prognosis.

The remaining AML cases have cancer cells with normal
'"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-2092
Ohio State University
1-Aug-2007


Page: 1 2

Related biology news :

1. Aggressive subtype of breast cancer displays misbehavior of X chromosomes
2. Aggressive aquatic species invading Great Lakes
3. Testosterone replacement therapy: How safe for aging men?
4. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
5. Under magnetic force, nanoparticles may deliver gene therapy
6. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Stem cell therapy rescues motor neurons in ALS model
8. Study identifies new gene therapy tools for inherited blindness
9. Breast cancer and hormone therapy -- A looking-glass mirror?
10. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
11. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/4/2019)... ... 02, 2019 , ... Stay on top of current hot topics through free ... to all webinars is free, so be sure to register today to save your ... http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , August 27 – ...
(Date:8/1/2019)... ... July 31, 2019 , ... Molecular ... launch of the next generation of its FLIPR® Penta High-Throughput Cellular Screening System. ... FLIPR® platform for monitoring of G-protein-coupled receptors (GPCRs) and ion channels, offering a ...
(Date:7/24/2019)... ... July 24, 2019 , ... NDA Partners Chairman Carl ... with more than 20 years of experience working in scientific research and FDA-regulated ... as an Expert Consultant. , Dr. Hartzfeld has experience in all aspects of ...
Breaking Biology News(10 mins):
(Date:8/14/2019)... STATE COLLEGE, Pa. (PRWEB) , ... August 13, ... ... leader in nuclear receptor and in vitro toxicology testing solutions, announced the appointment ... of healthcare industry experience to the Board. , Mark McLoughlin will lend his ...
(Date:8/6/2019)... ... 06, 2019 , ... The San Diego Biotechnology Network (SDBN) ... SDBN BUZZ podcast focused on connecting the region’s biotech community and discussing topics ... the region and attract external employers, investors, scientists, and others who wish to ...
(Date:8/4/2019)... (PRWEB) , ... August 02, 2019 , ... Cirtec Medical ... invasive devices, today announced that it has begun construction on a 30,000 sq. ft. ... 15 miles from San Jose. , The facility, which is expected to be ...
(Date:7/19/2019)... ... July 18, 2019 , ... Global precision motion and ... current piezo motion facilities in Lederhose, Germany, increasing their current footprint by half ... assembly production in addition to general office space, a significant increase to its ...
Breaking Biology Technology:
Cached News: